Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024

Euro Surveill. 2024 Aug;29(31):2400459. doi: 10.2807/1560-7917.ES.2024.29.31.2400459.

Abstract

As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.

Keywords: Bordetella pertussis; FIM2 fimbriae; macrolide resistance; pertactin production; post-covid-19 resurgence.

MeSH terms

  • Adult
  • Anti-Bacterial Agents* / pharmacology
  • Bacterial Outer Membrane Proteins / genetics
  • Bordetella pertussis* / drug effects
  • Bordetella pertussis* / genetics
  • Bordetella pertussis* / isolation & purification
  • Child
  • Child, Preschool
  • Drug Resistance, Bacterial
  • France / epidemiology
  • Genotype
  • Humans
  • Incidence
  • Macrolides* / pharmacology
  • Microbial Sensitivity Tests
  • Virulence Factors, Bordetella / genetics
  • Whole Genome Sequencing
  • Whooping Cough* / epidemiology
  • Whooping Cough* / microbiology

Substances

  • Macrolides
  • Anti-Bacterial Agents
  • pertactin
  • Bacterial Outer Membrane Proteins
  • Virulence Factors, Bordetella